133 related articles for article (PubMed ID: 7941593)
1. [Synergistic cytotoxic effects of chemotherapy in colon tumor cells by simultaneous inhibition of de novo and salvage energy metabolism pathways].
Szekeres T; Fritzer M; Schön HJ; Findenig G; Lhotka C
Wien Klin Wochenschr; 1994; 106(14):459-63. PubMed ID: 7941593
[TBL] [Abstract][Full Text] [Related]
2. Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines.
Szekeres T; Schuchter K; Chiba P; Ressmann G; Lhotka C; Gharehbaghi K; Szalay SM; Pillwein K
Biochem Pharmacol; 1993 Dec; 46(11):1903-7. PubMed ID: 7903533
[TBL] [Abstract][Full Text] [Related]
3. Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells.
Fritzer-Szekeres M; Salamon A; Grusch M; Horvath Z; Höchtl T; Steinbrugger R; Jäger W; Krupitza G; Elford HL; Szekeres T
Biochem Pharmacol; 2002 Aug; 64(3):481-5. PubMed ID: 12147300
[TBL] [Abstract][Full Text] [Related]
4. [The ribonucleotide reductase enzyme as a target for enzyme-directed chemotherapy effects of trimidox (3,4,5-trihydroxybenzohydroxamidoxim), a new inhibitor of ribonucleotide reductases].
Findenig G; Vielnascher E; Göbl R; Fritzer-Szekeres M; Szekeres T
Wien Klin Wochenschr; 1995; 107(22):694-7. PubMed ID: 8533431
[TBL] [Abstract][Full Text] [Related]
5. Role of differentiation induction in action of purine antimetabolites.
Weber G; Hata Y; Prajda N
Pharm World Sci; 1994 Apr; 16(2):77-83. PubMed ID: 8032345
[TBL] [Abstract][Full Text] [Related]
6. Synergistic action of tiazofurin and difluorodeoxycytidine on differentiation and cytotoxicity.
Ban J; Weber G
Biochem Biophys Res Commun; 1992 Apr; 184(2):551-9. PubMed ID: 1349474
[TBL] [Abstract][Full Text] [Related]
7. Synergistic growth inhibitory and differentiating effects of trimidox and tiazofurin in human promyelocytic leukemia HL-60 cells.
Szekeres T; Fritzer M; Strobl H; Gharehbaghi K; Findenig G; Elford HL; Lhotka C; Schoen HJ; Jayaram HN
Blood; 1994 Dec; 84(12):4316-21. PubMed ID: 7994048
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.
Santini V; Bernabei A; Gozzini A; Scappini B; Zoccolante A; D'Ippolito G; Figuccia M; Ferrini PR
Haematologica; 1997; 82(1):11-5. PubMed ID: 9172997
[TBL] [Abstract][Full Text] [Related]
9. The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
Sigmond J; Kamphuis JA; Laan AC; Hoebe EK; Bergman AM; Peters GJ
Biochem Pharmacol; 2007 May; 73(10):1548-57. PubMed ID: 17324380
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase.
Szekeres T; Gharehbaghi K; Fritzer M; Woody M; Srivastava A; van't Riet B; Jayaram HN; Elford HL
Cancer Chemother Pharmacol; 1994; 34(1):63-6. PubMed ID: 8174204
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Csoka K; Liliemark J; Larsson R; Nygren P
Semin Oncol; 1995 Aug; 22(4 Suppl 11):47-53. PubMed ID: 7481845
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea and trimidox enhance the radiation effect in human pancreatic adenocarcinoma cells.
Leyden D; Ahmed N; Hassan HT
Anticancer Res; 2000; 20(1A):133-8. PubMed ID: 10769645
[TBL] [Abstract][Full Text] [Related]
13. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
14. The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro.
Lech-Maranda E; Korycka A; Robak T
Haematologica; 2000 Jun; 85(6):588-94. PubMed ID: 10870114
[TBL] [Abstract][Full Text] [Related]
15. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells.
Bhalla K; Holladay C; Lutzky J; Ibrado AM; Bullock G; Jasiok M; Singh S
Gynecol Oncol; 1992 Apr; 45(1):32-9. PubMed ID: 1601333
[TBL] [Abstract][Full Text] [Related]
16. Critical issues in chemotherapy with tiazofurin.
Weber G
Adv Enzyme Regul; 1989; 29():75-95. PubMed ID: 2699155
[TBL] [Abstract][Full Text] [Related]
17. Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells.
Myette MS; Elford HL; Chitambar CR
Cancer Lett; 1998 Jul; 129(2):199-204. PubMed ID: 9719462
[TBL] [Abstract][Full Text] [Related]
18. Regulation of de novo and salvage pathways in chemotherapy.
Weber G; Nagai M; Natsumeda Y; Ichikawa S; Nakamura H; Eble JN; Jayaram HN; Zhen WN; Paulik E; Hoffman R
Adv Enzyme Regul; 1991; 31():45-67. PubMed ID: 1877399
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent synergistic action of tiazofurin and dipyridamole on hepatoma 3924A cells.
Jayaram HN; Murayama K; Pillwein K; Zhen W; Weber G
Cancer Chemother Pharmacol; 1992; 31(2):93-6. PubMed ID: 1451238
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
Bouffard DY; Momparler LF; Momparler RL
Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
